Pharem, a Greentech frontrunner in enzyme-based water treatment solutions, has joined forces with the global biopharmaceutical company AstraZeneca to develop sustainable water treatment solutions. Using Pharem's platform Zymatic, the companies target one or several waste streams from API manufacturing to find new ways of treatment using enzymes.
Pharem wins the BlueInvest Award in the category Circular Economy and Preventing Ocean Pollution. A highly regarded award from EUs own initiative to invest in the Blue Economy
Pharem Biotech and Leading Cities (AcceliGOV) is now accepting applications from any wastewater treatment plant or industrial water processor. The application is open until mid-March for a funded water treatment pilot. The pilot is worth $100,000 targeting organic micropollutants and unwanted organic compounds to reduce chemical emissions to our water environments
Pharem have successfully increased their portfolio of customer related projects, both in the Nordic countries but also internationally. To accelerate these projects Pharem have been granted financing from Nefco.
We proudly announce that Pharem, with its technology Zymatic, has been awarded the Solution of the Year in the #AcceliCITY Resilience Challengas 2021! With Zymatic, Pharem creates affordable solutions for treatment of micropollutants originating from society. #impact #sustainability #enzymes #watertreatment #leadingcities
Pharem have, with its water treatment brand Zymatic, been selected as one of only 20 SMEs to join the InnoWise Scale project. The joint project objective is to find innovative solutions for various water scarcity challenges in Southern Europe.
Zymatic has been chosen to participate in the international project “Green Ultrafiltration Water Cleaning Technologies”. The project will investigate various technologies and combination of technologies for treatment of contaminants of emerging concern (CECs).
Since its launch a few months ago, pCure has had steadily increased sales growth and interest. Pharem´s owners have therefore decided to place the brand, and IP, in its own company. The new company is in line with the ongoing strategy to simplify the interaction between different Pharem products. The strategy will open up for partners and investors with a specific interest in pCure.
